Want to see SE:ARCOMA full AI Analyst Report?

Arcoma AB (ARCOMA) Price & Analysis

0 Followers

ARCOMA Stock Chart & Stats

kr7.20

-kr0.40(-3.79%)

At close: Mar 06 4:00 PM EST

kr7.20

-kr0.40(-3.79%)

Day’s Range― - ―

52-Week Rangekr6.16 - kr10.05

Previous CloseN/A

Volume10.05K

Average Volume (3M)22.73K

Market Cap

kr115.90M

Enterprise Valuekr96.73

Total Cash (Recent Filing)kr30.91M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)28.3

Beta0.11

Next Earnings

Oct 22, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.29

Shares Outstanding14,308,510

10 Day Avg. Volume31,356

30 Day Avg. Volume22,732

Financial Highlights & Ratios

PEG Ratio-0.36

Price to Book (P/B)1.41

Price to Sales (P/S)0.80

P/FCF Ratio8.02

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.55

Revenue Forecast (FY)kr135.00M

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetMinimal leverage gives Arcoma financial flexibility to absorb demand swings, fund product development and support customer installations without heavy interest burdens. Rising equity further strengthens resilience as the business manages uneven operating performance.

Return To ProfitabilityThe shift from earlier loss years to positive earnings indicates improved operating viability. Although profitability remains below the 2024 peak, positive EBITDA and net income provide an earnings base that can compound if execution and demand stabilize.

Diversified Imaging Revenue ModelCombining equipment sales with service, parts, upgrades and software creates multiple monetization channels around clinical imaging deployments. This model can deepen customer relationships and provide aftermarket demand beyond each initial system sale.

Bears Say

Uneven Revenue TrendThe contrasting annual and TTM trends show that demand and order timing remain inconsistent. Such volatility makes capacity planning harder, reduces earnings visibility and may limit the company’s ability to sustain growth across healthcare procurement cycles.

Margin CompressionLower margins versus 2024 indicate weaker earnings efficiency and potential mix, pricing or cost pressure. If this persists, revenue growth will translate less effectively into profit and could constrain internally funded investment in products and market expansion.

Volatile Cash GenerationPositive current cash flow is encouraging, but the sharp decline and prior negative periods reveal working-capital and execution risk. Uneven conversion from earnings to cash can restrict flexibility for inventory, installations, development and customer support.

ARCOMA FAQ

What was Arcoma AB’s price range in the past 12 months?

Arcoma AB lowest stock price was kr6.16 and its highest was kr10.05 in the past 12 months.

What is Arcoma AB’s market cap?

Arcoma AB’s market cap is kr115.90M.

When is Arcoma AB’s upcoming earnings report date?

Arcoma AB’s upcoming earnings report date is Oct 22, 2026 which is in 60 days.

How were Arcoma AB’s earnings last quarter?

Arcoma AB released its earnings results on Aug 20, 2026. The company reported kr0.022 earnings per share for the quarter, missing the consensus estimate of kr0.14 by -kr0.118.

Is Arcoma AB overvalued?

According to Wall Street analysts Arcoma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arcoma AB pay dividends?

Arcoma AB does not currently pay dividends.

What is Arcoma AB’s EPS estimate?

Arcoma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arcoma AB have?

Arcoma AB has 14,308,510 shares outstanding.

What happened to Arcoma AB’s price movement after its last earnings report?

Arcoma AB reported an EPS of kr0.022 in its last earnings report, missing expectations of kr0.14. Following the earnings report the stock price went up 5.211%.

Which hedge fund is a major shareholder of Arcoma AB?

Currently, no hedge funds are holding shares in SE:ARCOMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Arcoma AB

Arcoma AB is a global provider that designs, manufactures, and supplies cutting-edge radiology solutions. Their product line features advanced digital x-ray and radiography systems. These versatile systems are suitable for a wide array of radiographic applications and are utilized across various clinical environments, including general practice, musculoskeletal, thoracic, pediatric, and trauma/resuscitation units. The company distributes its products through a network of OEM partners. Arcoma AB was founded in 1990 and is headquartered in Växjö, Sweden.